2024
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo A, Monzonís X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Frontiers In Pharmacology 2024, 15: 1398419. PMID: 38711991, PMCID: PMC11070789, DOI: 10.3389/fphar.2024.1398419.Peer-Reviewed Original ResearchAnti-EGFR therapyResistance to anti-EGFR therapySecondary resistance to anti-EGFR therapiesColorectal cancerEmergence of acquired resistanceExtracellular domain of EGFRMetastatic colorectal cancerBlood of patientsClinical cohort studyDomain of EGFRMulti-drug treatmentBenefits of rechallengeEGFR blockadePotential therapeutic strategyAnti-EGFRClinical benefitTumor cellsGenomic alterationsLiquid biopsyCohort studyClinical trialsTherapeutic strategiesTherapyPatientsRechallenge
2022
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge. Cancers 2022, 14: 1931. PMID: 35454838, PMCID: PMC9027936, DOI: 10.3390/cancers14081931.Peer-Reviewed Original ResearchMechanisms of resistanceNon-small cell lung cancerEGFR-mutant tumorsPercentage of non-small cell lung cancerCell lung cancerMultiple mechanisms of resistanceEGFR tumorsPotential therapeutic strategyClinical benefitToxicity profileTreatment optionsLung cancerFrequent alterationsTherapeutic strategiesAcquired mechanismsOsimertinibTumorMultiple mechanismsTreatmentEGFRIncreased useCancer